Telehealth Platforms Truemeds Raises $22 million in a Series B Round of Funding The company plans to utilize the funds to accelerate growth in the untapped domestic market and expand its coverage across the country

By Akshit Pushkarna

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Truemeds' Founders Akshat Nayyar and Dr. Kunal Wani

Telehealth platform Truemeds announced that they have raised $22 million in its series B funding round. The funding was led by private equity fund Westbridge Capital and also saw participation from existing investors InfoEdge Ventures, Asha Impact and IAN Fund. The round witnessed oversubscription from new and existing investors however the company decided to cap the raise to $22 million.

Founded by Ex-Abbott executives, Akshat Nayyar and Dr.Kunal Wani, Truemeds was founded in 2019 and is headquartered in Mumbai. The company last raised $5 million in a Series A funding round back in June, 2021. Truemeds plans to utilize the funds to accelerate growth in the untapped domestic market and expand its coverage across the country.

The telehealth industry, of which Truemeds is a key player, is expected to enjoy a significant growth in business in the coming years. A Statista report released in 2020 predicted the industry to generate revenue a total revenue of $5.5 billion by 2025. The company has seen a good growth in demand owed to its proprietary algorithm and tele-consultation, through which they are able to recommend best value medicines to customers with precise scientific matching.

India is one of the very few markets where Truemeds has pseudo-categorisation of medicines in branded and generic-generic to create different price tiers between them. 95 percent of the drugs sold in India are off-patent (thus technically generics). There is absolutely no difference in the scientific composition of generics and branded drugs.

This market is growing at 1.5 times the overall pharmaceutical market and following the US landscape where the generics prescription share moved from 40% in 2005 to over 85 percent in 2019. The market move towards generics is inevitable, Truemeds co-founder Akshat Nayyar believes, and he believes his company will lead that change.

Commenting on the development, Nayyar said, "We are overwhelmed by the confidence our incoming and existing investors have shown in us. We are excited to welcome Westbridge Capital to join us as we make Truemeds a household name."

Sandeep Singhal, Managing Director, Westbridge Capital, commented, "We are excited to partner with Truemeds as they create value for patients by delivering high quality drugs at extremely affordable prices at the patients' doorstep. The founding team's strong category understanding has resulted in the success at Truemeds and we are excited to help take the company to the next level."

Akshit Pushkarna

Former Features Writer

Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

Business News

UnitedHealth Group's Former CEO Is Returning to the Role — and Receiving a $60 Million Award

Stephen Hemsley is back in charge after leading UnitedHealth Group from 2006 to 2017.

Business News

IBM Replaced Hundreds of HR Workers With AI, According to Its CEO

IBM CEO Arvind Krishna said the move led to more hiring in other areas.

Business News

Starbucks Employees Aren't Happy With the New Dress Code

Some Starbucks employees are walking out over the changes.

Money & Finance

The Recession Mistake That Cost My Business $1.5 Million — and the Decision That Put Us Back on Top

Two recessions, two very different responses: One cost me millions, and the other grew my business 10% that same year.

Starting a Business

A Cambodian Refugee Paralyzed By Polio Says 'Not Much' Was Expected of Him. He and His Wife Built a Multimillion-Dollar Business That Beat All Odds.

Steve and Brittany Yeng were discouraged from pursuing their unique idea, but they didn't listen to the naysayers.